Skip to main content
Year archive

Ascentage Pharma Group International — 2021 filings

All 88 regulatory filings released by Ascentage Pharma Group International (6855) in 2021, sourced directly from the official regulator.

88 Filings
2021 Period
2021 filings (88)
Filing Released Lang
Voluntary Announcement - Ascentage Pharma Presents Results of Six Studies of Three Novel Drug Candidates under Development (Olverembatinib, APG-2575, and APG-1252) at the 63rd American Society of Hem
Regulatory Filings
2021-12-14 English
Voluntary Announcement - Ascentage Pharma Announces CDE's Approval for the Phase II Pivotal Study in China of the Bcl-2 Inhibitor Lisaftoclax (APG-2575) for the Treatment of Relapsed/ Refrac
Regulatory Filings
2021-12-13 English
VOLUNTARY ANNOUNCEMENT - Ascentage Pharma and Clover Enter into Clinical Collaboration to Jointly Develop IAP Antagonist, APG-1387, in Combination with Recombinant Human TRIAL-Trimer Fusion Protein, S
Regulatory Filings
2021-12-09 English
Next Day Disclosure Return
Transaction in Own Shares
2021-12-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2021
Regulatory Filings
2021-12-03 English
APPOINTMENT OF CHIEF FINANCIAL OFFICER
Board/Management Information
2021-11-29 English
Inside Information - Ascentage Pharma Announces Approval by NMPA for China's First Approved Third-Generation BCR-ABL TKI HQP1351 (Olverembatinib)
Regulatory Filings
2021-11-25 English
Voluntary Announcement - Ascentage Pharma's core drug candidate HQP1351 (Olverembatinib) Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia
Regulatory Filings
2021-11-22 English
Next Day Disclosure Return
Transaction in Own Shares
2021-11-11 English
ON-MARKET REPURCHASE OF SHARES
Transaction in Own Shares
2021-11-11 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares
2021-11-10 English
ON-MARKET REPURCHASE OF SHARES
Transaction in Own Shares
2021-11-10 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares
2021-11-09 English
ON-MARKET REPURCHASE OF SHARES
Transaction in Own Shares
2021-11-09 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares
2021-11-08 English
ON-MARKET REPURCHASE OF SHARES
Transaction in Own Shares
2021-11-08 English
Voluntary Announcement - Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4/6 Inhibitor IBRANCE (Palbociclib) in the Treatment
Regulatory Filings
2021-11-08 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares
2021-11-05 English
ON-MARKET REPURCHASE OF SHARES
Transaction in Own Shares
2021-11-05 English
Voluntary Announcement - Abstracts on six studies of Ascentage Pharma's three drug candidates under development (Olverembatinib, APG-2575, and APG-1252) have been selected for oral presentation a
Regulatory Filings
2021-11-05 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares
2021-11-04 English
ON-MARKET REPURCHASE OF SHARES
Transaction in Own Shares
2021-11-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2021
Regulatory Filings
2021-11-04 English
RESIGNATION OF CHIEF FINANCIAL OFFICER
Board/Management Information
2021-11-01 English
COMPLETION OF THE ISSUANCE OF UNLISTED WARRANTS UNDER SPECIFIC MANDATE
Capital/Financing Update
2021-10-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2021
Regulatory Filings
2021-10-07 English
Voluntary Announcement - Ascentage Pharma's MDM2-p53 Inhibitor APG-115 Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melano
Regulatory Filings
2021-09-23 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON SEPTEMBER 20, 2021
Declaration of Voting Results & Voting Rights Announcements
2021-09-20 English
(1) DISCLOSEABLE TRANSACTIONS - SUBSCRIPTION OF COMMERCIAL PAPER AND STRUCTURED FINANCIAL PRODUCTS AND (2) SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2021 INTERIM REPORT
Capital/Financing Update
2021-09-10 English
VOLUNTARY ANNOUNCEMENT - Ascentage Pharma Announces Latest Data of Its Bcl-2/Bcl-xL Inhibitor APG-1252 Combined with Osimertinib in Patients with EGFR TKI-Resistant Non-Small Cell Lung Cancer
Regulatory Filings
2021-09-09 English
INTERIM REPORT 2021
Interim / Quarterly Report
2021-09-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2021
Share Issue/Capital Change
2021-09-06 English
NOTICE OF EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement
2021-08-31 English
FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON SEPTEMBER 20, 2021
Proxy Solicitation & Information Statement
2021-08-31 English
(1) CONNECTED TRANSACTION - PROPOSED GRANT OF RSUs TO CONNECTED SELECTED PERSONS&#x3b; (2) PROPOSED GRANT OF RSU SPECIFIC MANDATE TO ISSUE SHARES UNDER THE 2021 RSU SCHEME&#x3b; (3) PROPOSED GRANT OF
Proxy Solicitation & Information Statement
2021-08-31 English
RETIREMENT OF CHIEF OPERATING OFFICER
Board/Management Information
2021-08-30 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2021
Regulatory Filings
2021-08-30 English
ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2021
Interim / Quarterly Report
2021-08-24 English
NOTICE OF BOARD MEETING
Regulatory Filings
2021-08-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2021
Regulatory Filings
2021-08-05 English
DELAY IN DESPATCH OF CIRCULAR IN RELATION TO (1) PROPOSED ISSUANCE OF UNLISTED WARRANTS UNDER SPECIFIC MANDATE&#x3b; AND (2) CONNECTED TRANSACTION - PROPOSED GRANT OF AWARDS UNDER THE 2021 RSU SCHEME
Regulatory Filings
2021-07-30 English
Voluntary Announcement - Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325
Capital/Financing Update
2021-07-29 English
Next Day Disclosure Return
Share Issue/Capital Change
2021-07-26 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change
2021-07-23 English
SUPPLEMENTAL ANNOUNCEMENT - CONNECTED TRANSACTION CANCELLATION OF PROPOSED GRANT OF AWARDS AND PROPOSED RE-GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO INDEPENDENT NON-EXECUTIVE DIRECTORS
Board/Management Information
2021-07-23 English
COMPLETION OF ISSUANCE OF NEW SHARES UNDER GENERAL MANDATE
Capital/Financing Update
2021-07-23 English
Voluntary Announcement - Ascentage Pharma's MDM2-p53 Inhibitor, APG-115 (Alrizomadlin), Received an Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma
Regulatory Filings
2021-07-21 English
Voluntary Announcement - Ascentage Pharma Establishes Cooperation with the US National Cancer Institute to advance the Clinical Development of Ascentage Pharma's Bcl-2/Bcl-xL inhibitor APG-1
Regulatory Filings
2021-07-19 English
CONNECTED TRANSACTION - PROPOSED GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO INDEPENDENT NON-EXECUTIVE DIRECTORS APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER
Regulatory Filings
2021-07-14 English
(I) INSIDE INFORMATION - ENTRY INTO OF THE HQP1351 COLLABORATION AND LICENSE AGREEMENT AND THE APG- 2575 COMBINATION THERAPY STRATEGIC COLLABORATION AND CLINICAL TRIAL AGREEMENT&#x3b; (II) ISSUANCE OF
Capital/Financing Update
2021-07-14 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2021
Regulatory Filings
2021-07-06 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change
2021-06-29 English
2020 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information
2021-06-29 English
CLARIFICATION ANNOUNCEMENT - GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO THE INDEPENDENT SELECTED PERSONS
Regulatory Filings
2021-06-25 English
UPDATE ANNOUNCEMENT - GRANT OF AWARDS UNDER THE 2021 RSU SCHEME
Capital/Financing Update
2021-06-18 English
Voluntary Announcement - Ascentage Pharma Announces IND Clearance by the US FDA for APG-2575 as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors
Capital/Financing Update
2021-06-15 English
Voluntary Announcement - Ascentage Pharma Delivers Oral Presentation Featuring Updated Data Demonstrating Promising Efficacy and Safety of APG-2575 in Patients with Relapsed or Refractory CLL/SLL
Regulatory Filings
2021-06-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2021
Share Issue/Capital Change
2021-06-04 English
Terms of Reference for Audit Committee
Governance Information
2021-05-26 English
SUPPLEMENTAL ANNOUNCEMENT - GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND CONNECTED TRANSACTION PROPOSED GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO CHIEF COMMERCIAL OFFICER AND INDEPENDENT NON-EXEC
Regulatory Filings
2021-05-26 English
GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND CONNECTED TRANSACTION PROPOSED GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO CHIEF COMMERCIAL OFFICER
Capital/Financing Update
2021-05-21 English
Voluntary Announcement - Ascentage Pharma to Announce Updated Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) Demonstrating an Objective Response Rate of Around 80% and Therapeutic Potential in Patient
Regulatory Filings
2021-05-20 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 10, 2021
Declaration of Voting Results & Voting Rights Announcements
2021-05-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2021
Share Issue/Capital Change
2021-05-05 English
Voluntary Announcement - Ascentage Pharma to Announce Results from Four Clinical Studies at 2021 ASCO Annual Meeting, with Data of Two of Its Drug Candidates Including Lisaftoclax (APG-2575) to Be Rel
Regulatory Filings
2021-04-21 English
Voluntary Announcement - Presentation by Ascentage Pharma of Results of Latest Preclinical Studies at 2021 American Association for Cancer Research (AACR) Annual Meeting which Demonstrate Potential of
Investor Presentation
2021-04-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021
Share Issue/Capital Change
2021-04-09 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2021-04-08 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 10, 2021
AGM Information
2021-04-08 English
PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED REMUNERATION FOR DIRECTORS, PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2021-04-08 English
ANNUAL REPORT 2020
Annual Report
2021-04-08 English
CLARIFICATION ANNOUNCEMENT IN RELATION TO RESIGNATION OF NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
Board/Management Information
2021-04-01 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2020
Annual Report
2021-03-31 English
List of directors and their roles and functions
Board/Management Information
2021-03-31 English
Resignation of Non-executive Director and Appointment of Independent Non-executive Director
Board/Management Information
2021-03-31 English
Voluntary Announcement - Ascentage Pharma's First Third-Generation BCR-ABL Inhibitor in China Olverembatinib (HQP1351) Recommended for Breakthrough Therapy Designation
Regulatory Filings
2021-03-24 English
NOTICE OF BOARD MEETING
Regulatory Filings
2021-03-19 English
CLARIFICATION ANNOUNCEMENT IN RELATION TO GRANT OF AWARDS UNDER THE RSU SCHEME
Regulatory Filings
2021-03-19 English
Voluntary Announcement - Latest Results from Six Preclinical Studies to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021
Regulatory Filings
2021-03-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021
Share Issue/Capital Change
2021-03-03 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change
2021-02-11 English
CLOSING OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE
Capital/Financing Update
2021-02-11 English
PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE
Capital/Financing Update
2021-02-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2021
Share Issue/Capital Change
2021-02-03 English
ADOPTION OF THE 2021 RSU SCHEME
Regulatory Filings
2021-02-02 English
VOLUNTARY ANNOUNCEMENT - APG-2575 granted the fifth Orphan Drug Designation by the US FDA
Regulatory Filings
2021-01-29 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020
Regulatory Filings
2021-01-06 English
Voluntary Announcement - Ascentage Pharma Obtained its 9th Orphan Drug Designation from the US FDA in 2020, Setting a Record among Chinese Biopharmaceutical Companies
Regulatory Filings
2021-01-05 English